BioSpace News Archive

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on November 9-13, 2018, in San Francisco.

Today RHYTHM VENTURE CAPITAL announces the formation and first closing of its new venture capital fund. The new fund is called Rhythm Fund X and has formally accepted its first limited partners and aims to make its first investment by end of first quarter 2019.

EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - SME), a pioneer in 2D / 3D orthopedic medical imaging, will present its 2D / 3D collaborative data sharing solution, stereoVIEW, as well as its new online learning platform at the Francophone Radiology Days (JFR) Congress, which will take place October 12-15, at the Palais des Congrès in Paris.

Research published by PharmaForce International (PFI) shows the average number of oncology medical roles within the four regions of study: The United States, Europe, Japan and Latin America grew over the prior year.

Holzer & Holzer, LLC is investigating whether certain statements issued by Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) complied with federal securities laws.

Vee Technologies Ranks #1378 on the 2018 Inc. 5000 with Three-Year Revenue Growth of 343%

Today, Celmatix, the next-generation women’s health company, announced the initial findings of two landmark research studies that shed new light on biomarkers that are related to a woman’s fertility and her ovarian reserve.

On October 17, 2018, the Cannabis Act will come into force, marking a significant milestone in the Government of Canada’s commitment to legalizing and strictly regulating cannabis to keep it out of the hands of children and to keep profits away from criminals and organized crime

Arthrosurface®, Inc. announced today the official launch of its latest product, the stemless OVOMotion™ Shoulder Arthroplasty System with Inlay Glenoid.

Recommendations reflect evidence showing similar early cancer control and side effect rates with hypofractionated treatment, compared to longer courses of conventional radiation